Summit Therapeutics Inc. Selling, General and Administrative Expense
Summit Therapeutics Inc. (SMMT) reported Selling, General and Administrative Expense of GBP 523.00 thousand for the 3-month period ending 2020-03-31, per its 6-K filed 2020-06-02.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:SellingGeneralAndAdministrativeExpense · last filed 2020-06-02
- Summit Therapeutics Inc. selling general and administrative expense for the quarter ending 2020-03-31 was 523.00K GBP, a 68.40% decline year-over-year.
- Summit Therapeutics Inc. selling general and administrative expense for the quarter ending 2019-10-31 was 4.37M GBP, a 6.17% decline year-over-year.
- Summit Therapeutics Inc. selling general and administrative expense for the quarter ending 2019-07-31 was 1.20M GBP, a 48.26% decline year-over-year.
- Summit Therapeutics Inc. selling general and administrative expense for the quarter ending 2019-04-30 was 1.66M GBP, a 28.91% decline year-over-year.
| Period end | Selling General And Administrative Expense 3 month | Selling General And Administrative Expense 3 month as first filed | Selling General And Administrative Expense 6 month | Selling General And Administrative Expense 6 month as first filed | Selling General And Administrative Expense 9 month | Selling General And Administrative Expense 9 month as first filed | Selling General And Administrative Expense 11 month | Selling General And Administrative Expense 12 month | Selling General And Administrative Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|
| 2020-03-31 | 523.00K GBP 6-K · filed 2020-06-02 | ||||||||
| 2019-12-31 | 9.88M GBP 20-F · filed 2020-04-30 | ||||||||
| 2019-10-31 | 4.37M GBP 6-K · filed 2019-12-17 | 5.57M GBP derived: sum of 2 quarters · filed 2019-12-17 | 7.23M GBP 6-K · filed 2019-12-17 | ||||||
| 2019-07-31 | 1.20M GBP 6-K · filed 2019-10-11 | 2.86M GBP 6-K · filed 2019-10-11 | |||||||
| 2019-04-30 | 1.66M GBP 6-K · filed 2019-06-12 | ||||||||
| 2019-03-31 | 2.37M GBP 6-K · filed 2020-06-02 | ||||||||
| 2019-01-31 | 3.02M GBP derived: 20-F 12 month − 6-K 9 month · filed 2020-04-30 | 7.67M GBP derived: sum of 2 quarters · filed 2020-04-30 | 10.00M GBP derived: sum of 3 quarters · filed 2020-04-30 | 12.33M GBP 20-F · filed 2020-04-30 | 12.34M GBP 20-F · filed 2019-03-29 | ||||
| 2018-10-31 | 4.65M GBP 6-K · filed 2019-12-17 | 4.66M GBP 6-K · filed 2018-12-11 | 6.98M GBP derived: sum of 2 quarters · filed 2019-12-17 | 9.31M GBP 6-K · filed 2019-12-17 | 9.32M GBP 6-K · filed 2018-12-11 | 14.34M GBP derived: sum of 4 quarters · filed 2020-04-30 | |||
| 2018-07-31 | 2.33M GBP 6-K · filed 2019-10-11 | 2.71M GBP 6-K · filed 2018-09-20 | 4.66M GBP 6-K · filed 2019-10-11 | 5.38M GBP 6-K · filed 2018-09-20 | 9.69M GBP derived: sum of 3 quarters · filed 2020-04-30 | 11.67M GBP derived: sum of 4 quarters · filed 2020-04-30 | |||
| 2018-04-30 | 2.33M GBP 6-K · filed 2019-06-12 | 2.67M GBP 6-K · filed 2018-06-05 | 7.36M GBP derived: sum of 2 quarters · filed 2020-04-30 | 9.34M GBP derived: sum of 3 quarters · filed 2020-04-30 | 11.83M GBP derived: sum of 4 quarters · filed 2020-04-30 | ||||
| 2018-01-31 | 5.03M GBP derived: 20-F 12 month − 6-K 9 month · filed 2020-04-30 | 7.01M GBP derived: sum of 2 quarters · filed 2020-04-30 | 9.50M GBP derived: sum of 3 quarters · filed 2020-04-30 | 11.94M GBP 20-F · filed 2020-04-30 | 12.00M GBP 20-F · filed 2018-04-13 | ||||
| 2017-10-31 | 1.98M GBP 6-K · filed 2018-12-11 | 4.47M GBP derived: sum of 2 quarters · filed 2018-12-11 | 6.90M GBP 6-K · filed 2018-12-11 | ||||||
| 2017-07-31 | 2.49M GBP 6-K · filed 2018-09-20 | 4.92M GBP 6-K · filed 2018-09-20 | |||||||
| 2017-04-30 | 2.43M GBP 6-K · filed 2018-06-05 | ||||||||
| 2017-01-31 | 8.28M GBP 20-F · filed 2019-03-29 | ||||||||
| 2016-01-31 | 4.77M GBP 20-F · filed 2018-04-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |